Price
821.75
+0.93%52W Range
Market Cap
₹16,152.57 Cr
Traded: ₹2.93 Cr (0.02%) 0.0x
Free Float: ₹1,615.26 Cr (0.18% of FF traded)
Volume · 60D trend
35.57 K 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Sales | +9.0% | +6.0% | +9.0% | -- | +14.0% | Accelerating |
| ROE | +16.0% | +11.0% | +13.0% | -- | -- | Stable |
| Return | +2.0% | +1.0% | +1.0% | -16.0% | -- | Stable |
| Profit | +0.0% | -9.0% | +28.0% | -- | +26.0% | Stable |
Quarterly Results
Mar 2023
Dec 2022
Sep 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,150 | 1,848 | 1,876 | 1,910 | 1,711 | 1,770 | 1,693 | 1,648 | 1,562 | 1,517 | 1,631 | 1,595 | 1,486 | 1,406 | 1,509 | 1,475 |
| Expenses | 1,818 | 1,620 | 1,585 | 1,594 | 1,430 | 1,498 | 1,433 | 1,409 | 1,325 | 1,257 | 1,364 | 1,387 | 1,287 | 1,203 | 1,274 | 1,244 |
| Operating Profit | 332 | 228 | 292 | 316 | 281 | 271 | 260 | 239 | 237 | 260 | 266 | 208 | 199 | 204 | 235 | 231 |
| OPM % | 15.0% | 12.0% | 16.0% | 17.0% | 16.0% | 15.0% | 15.0% | 15.0% | 15.0% | 17.0% | 16.0% | 13.0% | 13.0% | 14.0% | 16.0% | 16.0% |
| Other Income | 15 | 2 | -27 | 8 | 6 | 14 | 10 | 30 | 2 | 4 | 3 | 10 | 12 | 1 | 0 | 0 |
| Interest | 28 | 23 | 23 | 24 | 24 | 25 | 22 | 19 | 13 | 11 | 15 | 16 | 14 | 14 | 15 | 12 |
| Depreciation | 98 | 89 | 80 | 76 | 74 | 69 | 70 | 71 | 69 | 69 | 69 | 68 | 66 | 74 | 67 | 68 |
| Profit Before Tax | 222 | 119 | 162 | 224 | 190 | 192 | 178 | 180 | 157 | 183 | 185 | 135 | 130 | 116 | 154 | 151 |
| Tax % | 22.0% | -70.0% | 18.0% | 18.0% | 19.0% | 18.0% | 23.0% | 15.0% | 14.0% | 3.0% | 2.0% | -1.0% | 7.0% | -31.0% | 21.0% | 12.0% |
| Net Profit | 172 | 202 | 132 | 184 | 154 | 157 | 138 | 153 | 135 | 178 | 180 | 137 | 121 | 153 | 122 | 133 |
| Exceptional Items | 0 | -25 | -42 | 0 | 0 | 0 | 0 | 13 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Rs) | 8.8 | 10.3 | 6.8 | 9.4 | 7.8 | 8.0 | 7.0 | 7.8 | 6.8 | 9.1 | 9.2 | 7.0 | 6.1 | 7.8 | 6.2 | 6.8 |
| Sales Growth (YoY) | 25.7% | 4.4% | 10.8% | 15.9% | 9.5% | 16.7% | 3.8% | 3.3% | 5.1% | 7.9% | 8.1% | 8.1% | -- | -- | -- | -- |
| Sales Growth (QoQ) | 16.3% | -1.5% | -1.8% | 11.6% | -3.3% | 4.5% | 2.7% | 5.5% | 3.0% | -7.0% | 2.3% | 7.3% | 5.7% | -6.8% | 2.3% | -- |
| OP Growth (YoY) | 18.1% | -15.9% | 12.3% | 32.2% | 18.6% | 4.2% | -2.3% | 14.9% | 19.1% | 27.5% | 13.2% | -10.0% | -- | -- | -- | -- |
| OP Growth (QoQ) | 45.6% | -21.9% | -7.6% | 12.5% | 3.7% | 4.2% | 8.8% | 0.8% | -8.8% | -2.3% | 27.9% | 4.5% | -2.5% | -13.2% | 1.7% | -- |
| Profit Growth (YoY) | -- | 41.0% | 21.0% | 29.0% | 15.0% | -12.0% | -23.0% | 5.0% | 12.0% | 17.0% | 48.0% | 2.0% | 283.0% | 596.0% | -29.0% | -19.0% |
| EPS Growth (YoY) | 12.1% | 29.2% | -4.0% | 20.5% | 14.6% | -12.0% | -23.3% | 12.2% | 11.6% | 16.9% | 48.1% | 2.5% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -14.7% | 52.5% | -28.1% | 19.8% | -1.6% | 13.3% | -9.7% | 13.9% | -24.5% | -1.2% | 32.1% | 13.2% | -20.9% | 25.2% | -8.6% | -- |
| OP Margin | 15.4% | 12.3% | 15.6% | 16.5% | 16.4% | 15.3% | 15.4% | 14.5% | 15.2% | 17.1% | 16.3% | 13.0% | 13.4% | 14.5% | 15.6% | 15.7% |
| Net Margin | 8.0% | 10.9% | 7.0% | 9.6% | 9.0% | 8.9% | 8.2% | 9.3% | 8.6% | 11.7% | 11.0% | 8.6% | 8.1% | 10.9% | 8.1% | 9.0% |
| Material Cost % | -- | 28.8% | 28.2% | 27.0% | 23.8% | 30.0% | 26.0% | 26.0% | 25.2% | 25.0% | 28.3% | 28.9% | 27.8% | 30.8% | 30.1% | 30.0% |
| Employee Cost % | -- | 23.8% | 23.1% | 22.9% | 24.7% | 22.2% | 23.5% | 23.8% | 24.3% | 26.5% | 21.4% | 21.8% | 23.4% | 21.2% | 19.3% | 19.6% |
| P/S | 2.08 | 2.16 | 2.13 | 1.97 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 23.30 | 23.48 | 24.56 | 22.04 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 2.85 | 2.79 | 2.90 | 2.63 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Intimation regarding Appointment of Company Secretary of the Company.
Please find attached.
Please find attached herewith the Transcript of Post Result Conference Call held on 4th August, 2026.
Please find attached.
Please find attached herewith the Scrutinizer Report and Voting Results of the AGM held on 5th August, 2026.
Please find attached Proceedings of AGM held on 5th August, 2026.
Please find enclosed herewith Outcome of Board Meeting.
Please find attached Unaudited Financial Results for the Quarter ended 30th June, 2026.
Please find attached herewith Intimation for Investors Call Scheduled to be held on 4th August, 2026.
Alembic Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/08/2026 ,inter alia, to consider and approve Unaudited Financial ....
Alembic Pharmaceuticals Limited''s Partner NATCO Pharma Limited receives USFDA Tentative Approval for Olaparib Tablets 100 mg and 150 mg
Please find enclosed.
Please find enclosed herewith the copy of the Newspaper Publication published on 11th July, 2026.
Please find enclosed herewith a copy of the Notice of the 16th Annual General Meeting of the Company scheduled to be held on Wednesday, 5th August, 2026 at 4:00 p.m. IST.
Please find enclosed herewith the intimation of Record Date for payment of Dividend on Equity Shares for the Financial Year ended 31st March, 2026.
Please find enclosed herewith a copy of Annual Report of the Company for the Financial Year ended 31st March, 2026.
Please find enclosed herewith a copy of the Business Responsibility and Sustainability Report of the Company including Reasonable Assurance Report for the Financial Year ended 31st March, 2026.
Please find enclosed.
Please find enclosed Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulation, 2018 for the quarter ended 30th June, 2026.
Please find enclosed.
Please find enclosed herewith the Intimation of Re-affirmation of Credit Rating.
Alembic Pharmaceuticals Limited receives USFDA Final Approval for Oseltamivir Phosphate for Oral Suspension, 6mg/mL.
Alembic Pharmaceuticals Limited receives USFDA Final Approval for Dapsone Gel, 5%.
Please find enclosed.
Intimation of Closure of Trading Window.
Alembic Pharmaceuticals Limited received USFDA Tentative Approval for Binimetinib Tablets, 45 mg.
Please find enclosed herewith Intimation of One on One Meet.
Please find enclosed herewith Intimation of One on One Meet.
Please find enclosed herewith Intimation of One of One Meet.
Appointment of Mr. Sujit Bhayani as Non-Executive Independent Director of the Company w.e.f. 18th June, 2026.
Alembic Pharmaceuticals Limited receives USFDA Final Approval for Tretinoin Cream USP, 0.05%.
Please find enclosed herewith the Intimation regarding re-affirmation of credit rating on Commercial Paper
Please find enclosed.
Alembic Pharmaceuticals Limited receives USFDA Tentative Approval for Larotrectinib Capsules, 25 mg and 100 mg.
Please find enclosed.
Company has executed shareholders agreement
Please find enclosed herewith specimen copy of the Reminder Letter sent to the shareholders of the Company holding shares in physical form for updating KYC details.
Please find enclosed.
Please find enclosed.
Please find enclosed Intimation.
Alembic Pharmaceuticals Limited receives USFDA Final Approval for Levothyroxine Sodium Tablets USP.
Please find attached.
Newspaper Publication of Audited Financial Results as on 31st March, 2026.
Please find enclosed herewith Outcome of Board Meeting .
Please fin enclosed herewith Audited Financial Results for the quarter and Financial Year ended 31st March, 2026.
Please find attached.
Please find attached.
Please find attached.
Please find attached.
Alembic Pharmaceuticals Limited receives USFDA Tentative Approval for Darolutamide Tablets, 300 mg.
Annual Reports
15Credit Ratings
6Concalls
41Feb 2026
28 Feb 2026Feb 2026
28 Feb 2026Nov 2025
30 Nov 2025Aug 2025
31 Aug 2025May 2025
31 May 2025Feb 2025
28 Feb 2025Nov 2024
30 Nov 2024Aug 2024
31 Aug 2024May 2024
31 May 2024Feb 2024
29 Feb 2024Nov 2023
30 Nov 2023Aug 2023
31 Aug 2023May 2023
31 May 2023Feb 2023
28 Feb 2023Nov 2022
30 Nov 2022Aug 2022
31 Aug 2022May 2022
31 May 2022Feb 2022
28 Feb 2022Nov 2021
30 Nov 2021Aug 2021
31 Aug 2021May 2021
31 May 2021Jan 2021
31 Jan 2021Oct 2020
31 Oct 2020Jul 2020
31 Jul 2020Apr 2020
30 Apr 2020Mar 2020
31 Mar 2020Jan 2020
31 Jan 2020Oct 2019
31 Oct 2019Jul 2019
31 Jul 2019Apr 2019
30 Apr 2019Jan 2019
31 Jan 2019Oct 2018
31 Oct 2018May 2018
31 May 2018Jan 2018
31 Jan 2018Oct 2017
31 Oct 2017Apr 2017
30 Apr 2017Jan 2017
31 Jan 2017Oct 2016
31 Oct 2016Jul 2016
31 Jul 2016Apr 2016
30 Apr 2016Jan 2016
31 Jan 2016Held by ETFs
4 ETFs hold aplltd · sorted by weight
Held by Mutual Funds
18 schemes hold aplltd · sorted by weight